埃迪鲁单抗（INN：eldelumab；开发代号：BMS-936557[1]）或译依德鲁单抗，是一种抗CXCL10全人单克隆抗体（IgG1 κ型）[2][1]，设计用于治疗克罗恩病和溃疡性结肠炎。[3]
该药物由百时美施贵宝和Medarex开发。[4]
参考资料[编辑]
- ^ 1.0 1.1 Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn's & Colitis. April 2016, 10 (4): 418–28. PMC 4946756
. PMID 26721935. doi:10.1093/ecco-jcc/jjv224.
- ^ Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs. www.creativebiolabs.net. [2017-03-24].
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
- ^ Eldelumab. AdisInsight. Springer Nature Switzerland AG.
